Are there data for treating patients with metastatic NSCLC with BRAF nonV600E mutations with BRAF and MEK inhibitors?  

Are there any data regarding response to checkpoint inhibitors for these patients?  



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice